• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

移植肾后预测 HLA 细胞毒性 T 细胞表位靶点与 T 细胞介导排斥反应的关系。

Association of Predicted HLA T-Cell Epitope Targets and T-Cell-Mediated Rejection After Kidney Transplantation.

机构信息

KU Leuven, Department of Microbiology, Immunology and Transplantation, KU Leuven University, Leuven, Belgium; Histocompatibility and Immunogenetics Laboratory (HILA), Belgian Red Cross-Flanders, Mechelen, Belgium.

KU Leuven, Department of Microbiology, Immunology and Transplantation, KU Leuven University, Leuven, Belgium.

出版信息

Am J Kidney Dis. 2022 Dec;80(6):718-729.e1. doi: 10.1053/j.ajkd.2022.04.009. Epub 2022 Jun 9.

DOI:10.1053/j.ajkd.2022.04.009
PMID:35690154
Abstract

RATIONALE & OBJECTIVE: The relationship between human leukocyte antigen (HLA) molecular mismatches and T-cell-mediated rejection (TCMR) is unknown. We investigated the associations between the different donor HLA-derived T-cell targets and the occurrence of TCMR and borderline histologic changes suggestive of TCMR after kidney transplantation.

STUDY DESIGN

Retrospective cohort study.

SETTING & PARTICIPANTS: All kidney transplant recipients at a single center between 2004 and 2013 with available biopsy data and a DNA sample for high-resolution HLA donor/recipient typing (N = 893).

EXPOSURE

Scores calculated by the HLA matching algorithm PIRCHE-II and HLA eplet mismatches.

OUTCOME

TCMR, borderline changes suggestive of TCMR, and allograft failure.

ANALYTICAL APPROACH

Multivariable cause-specific hazards models were fit to characterize the association between HLA epitopes targets and study outcomes.

RESULTS

We found 277 patients developed TCMR, and 134 developed only borderline changes suggestive of TCMR on at least 1 biopsy. In multivariable analyses, only the PIRCHE-II scores for HLA-DRB1 and HLA-DQB1 were independently associated with the occurrence of TCMR and with allograft failure; this was not the case for HLA class I molecules. If restricted to rejection episodes within the first 3 months after transplantation, only the T-cell epitope targets originating from the donor's HLA-DRB1 and HLA-DQB1, but not class I molecules, were associated with the early acute TCMR. Also, the median PIRCHE-II score for HLA class II was statistically different between the patients with TCMR compared to the patients without TCMR (129 [IQR, 60-240] vs 201 [IQR, 96-298], respectively; P < 0.0001). These differences were not observed for class I PIRCHE-II scores.

LIMITATIONS

Observational clinical data and residual confounding.

CONCLUSIONS

In the absence of HLA-DSA, HLA class II but not class I mismatches are associated with early episodes of acute TCMR and allograft failure. This suggests that current immunosuppressive therapies are largely able to abort the most deleterious HLA class I-directed alloimmune processes; however, alloresponses against HLA-DRB1 and HLA-DQB1 molecular mismatches remain insufficiently suppressed.

PLAIN-LANGUAGE SUMMARY: Genetic differences in the human leukocyte antigen (HLA) complex between kidney transplant donors and recipients play a central role in T-cell-mediated rejection (TCMR), which can lead to failure of the transplanted kidney. Evaluating this genetic disparity (mismatch) in the HLA complex at the molecular (epitope) level could contribute to better prediction of the immune response to the donor organ posttransplantation. We investigated the associations of the different donor HLA-derived T-cell epitope targets and scores obtained from virtual crossmatch algorithms with the occurrence of TCMR, borderline TCMR, and graft failure after kidney transplantation after taking into account the influence of donor-specific anti-HLA antibodies. This study illustrates the greater importance of the molecular mismatches in class II molecules compared to class I HLA molecules.

摘要

背景与目的

人类白细胞抗原(HLA)分子错配与 T 细胞介导的排斥反应(TCMR)之间的关系尚不清楚。我们研究了不同供体 HLA 衍生 T 细胞靶标与肾移植后 TCMR 及提示 TCMR 的边缘组织学变化的发生之间的相关性。

研究设计

回顾性队列研究。

研究地点和参与者

2004 年至 2013 年间在一家单中心接受肾移植的所有患者,这些患者均具有可获得的活检数据和用于高分辨率 HLA 供体/受者分型的 DNA 样本(N=893)。

暴露

通过 HLA 匹配算法 PIRCHE-II 和 HLA 表位错配计算的评分。

结局

TCMR、提示 TCMR 的边缘改变和移植物失功。

分析方法

采用多变量因果风险模型来描述 HLA 表位靶标与研究结局之间的关联。

结果

我们发现 277 例患者发生 TCMR,134 例患者至少有 1 次活检出现仅提示 TCMR 的边缘改变。多变量分析显示,只有 HLA-DRB1 和 HLA-DQB1 的 PIRCHE-II 评分与 TCMR 的发生和移植物失功相关,而 HLA Ⅰ类分子则不然。如果仅将排斥反应限于移植后 3 个月内,仅来自供体 HLA-DRB1 和 HLA-DQB1 的 T 细胞表位靶标与早期急性 TCMR 相关,而不是 HLA Ⅰ类分子。此外,与无 TCMR 的患者相比,发生 TCMR 的患者的 HLA Ⅱ类 PIRCHE-II 评分中位数存在统计学差异(129[IQR,60-240]与 201[IQR,96-298];P<0.0001)。而 HLA Ⅰ类 PIRCHE-II 评分则没有观察到这种差异。

局限性

观察性临床数据和残余混杂因素。

结论

在没有 HLA-DSA 的情况下,HLA Ⅱ类而非 HLA Ⅰ类错配与早期急性 TCMR 和移植物失功相关。这表明目前的免疫抑制治疗在很大程度上能够阻止最具危害性的 HLA Ⅰ类同种免疫过程;然而,针对 HLA-DRB1 和 HLA-DQB1 分子错配的同种反应仍然没有得到充分抑制。

相似文献

1
Association of Predicted HLA T-Cell Epitope Targets and T-Cell-Mediated Rejection After Kidney Transplantation.移植肾后预测 HLA 细胞毒性 T 细胞表位靶点与 T 细胞介导排斥反应的关系。
Am J Kidney Dis. 2022 Dec;80(6):718-729.e1. doi: 10.1053/j.ajkd.2022.04.009. Epub 2022 Jun 9.
2
PIRCHE-II scores prove useful as a predictive biomarker among kidney transplant recipients with rejection: An analysis of indication and follow-up biopsies.PIRCHE-II 评分可作为移植肾排斥反应受者的预测性生物标志物:一项基于适应证和随访活检的分析。
Front Immunol. 2022 Aug 17;13:949933. doi: 10.3389/fimmu.2022.949933. eCollection 2022.
3
Molecular Mismatch Predicts T Cell-Mediated Rejection and De Novo Donor-Specific Antibody Formation After Living Donor Liver Transplantation.分子错配预测活体供肝移植后 T 细胞介导的排斥反应和新的供体特异性抗体形成。
Liver Transpl. 2021 Nov;27(11):1592-1602. doi: 10.1002/lt.26238. Epub 2021 Aug 23.
4
Eplet Mismatch Load and Occurrence of Donor-Specific Anti-HLA Antibodies, Rejection, and Graft Failure after Kidney Transplantation: An Observational Cohort Study.Eplet 错配负荷与供体特异性抗 HLA 抗体、排斥反应和肾移植后移植物失败的发生:一项观察性队列研究。
J Am Soc Nephrol. 2020 Sep;31(9):2193-2204. doi: 10.1681/ASN.2020010019. Epub 2020 Aug 6.
5
Analysis of T and B Cell Epitopes to Predict the Risk of Donor-Specific Antibody (DSA) Production After Kidney Transplantation: A Two-Center Retrospective Cohort Study.分析T细胞和B细胞表位以预测肾移植后供体特异性抗体(DSA)产生的风险:一项双中心回顾性队列研究。
Front Immunol. 2020 Aug 27;11:2000. doi: 10.3389/fimmu.2020.02000. eCollection 2020.
6
Association of HLA B- and T-cell molecular mismatches with HLA antibodies, rejection, and graft survival in pediatric kidney transplantation.HLA 分子错配与 HLA 抗体、排斥反应和儿童肾移植中移植物存活的关系。
Pediatr Transplant. 2024 Aug;28(5):e14773. doi: 10.1111/petr.14773.
7
HLA molecular mismatches and induced donor-specific tolerance in combined living donor kidney and hematopoietic stem cell transplantation.HLA 分子错配与诱导供者特异性耐受在联合活体供肾和造血干细胞移植中的作用。
Front Immunol. 2024 Mar 27;15:1377535. doi: 10.3389/fimmu.2024.1377535. eCollection 2024.
8
The number of donor HLA-derived T cell epitopes available for indirect antigen presentation determines the risk for vascular rejection after kidney transplantation.供者 HLA 衍生 T 细胞表位的数量可用于间接抗原呈递,决定了肾移植后血管排斥的风险。
Front Immunol. 2022 Aug 30;13:973968. doi: 10.3389/fimmu.2022.973968. eCollection 2022.
9
Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation.基于预测的间接可识别 HLA 表位的供受者匹配独立预测肾移植后新出现的供者特异性 HLA 抗体的发生率。
Am J Transplant. 2017 Dec;17(12):3076-3086. doi: 10.1111/ajt.14393. Epub 2017 Jul 28.
10
Association between PIRCHE-II scores and de novo allosensitization after reduction of immunosuppression during SARS-CoV-2 infection in kidney transplant recipients.新型冠状病毒感染期间降低免疫抑制剂治疗后肾移植受者 PIRCHE-II 评分与新生同种异体致敏的相关性。
Transpl Infect Dis. 2023 Apr;25(2):e14052. doi: 10.1111/tid.14052. Epub 2023 Mar 8.

引用本文的文献

1
donor-specific anti-HLA antibody risk stratification in kidney transplantation using a combination of B cell and T cell molecular mismatch assessment.使用B细胞和T细胞分子错配评估相结合的方法对肾移植中供体特异性抗HLA抗体进行风险分层
Front Immunol. 2025 Feb 25;16:1508796. doi: 10.3389/fimmu.2025.1508796. eCollection 2025.
2
Indirect presentation of mismatched human leukocyte antigen-B associates with outcomes of cord blood transplantation.不匹配的人类白细胞抗原-B的间接呈现与脐血移植的结果相关。
Br J Haematol. 2025 May;206(5):1406-1417. doi: 10.1111/bjh.20035. Epub 2025 Mar 10.
3
Advancing risk stratification in kidney transplantation: integrating HLA-derived T-cell epitope and B-cell epitope matching algorithms for enhanced predictive accuracy of HLA compatibility.
推进肾移植中的风险分层:整合源自人类白细胞抗原(HLA)的T细胞表位和B细胞表位匹配算法以提高HLA相容性的预测准确性
Front Immunol. 2025 Feb 11;16:1548934. doi: 10.3389/fimmu.2025.1548934. eCollection 2025.
4
Understanding HLA-DQ in renal transplantation: a mini-review.肾移植中对人类白细胞抗原-DQ的理解:一篇综述短文
Front Immunol. 2025 Feb 5;16:1525306. doi: 10.3389/fimmu.2025.1525306. eCollection 2025.
5
Predicted indirectly recognizable HLA epitopes scores and clinical outcomes after haploidentical stem cell transplantation in pediatric patients with relapsed neuroblastoma.复发神经母细胞瘤患儿单倍体相合干细胞移植后预测的间接可识别HLA表位评分及临床结局
Front Immunol. 2025 Jan 22;16:1517387. doi: 10.3389/fimmu.2025.1517387. eCollection 2025.
6
Predicted Indirectly Recognizable T-cell Epitope (PIRCHE) Load Correlates With Rejection Events After Simultaneous Pancreas-Kidney Transplantation.预测的间接可识别T细胞表位(PIRCHE)负荷与同期胰肾联合移植后的排斥反应事件相关。
Transplant Direct. 2025 Feb 7;11(3):e1764. doi: 10.1097/TXD.0000000000001764. eCollection 2025 Mar.
7
A walk through the development of human leukocyte antigen typing: from serologic techniques to next-generation sequencing.人类白细胞抗原分型的发展历程:从血清学技术到下一代测序
Clin Transplant Res. 2024 Dec 31;38(4):294-308. doi: 10.4285/ctr.24.0055. Epub 2024 Dec 11.
8
Improving long-term kidney allograft survival by rethinking HLA compatibility: from molecular matching to non-HLA genes.通过重新思考HLA相容性提高肾移植长期存活率:从分子匹配到非HLA基因
Front Genet. 2024 Oct 2;15:1442018. doi: 10.3389/fgene.2024.1442018. eCollection 2024.
9
Activation and Regulation of Indirect Alloresponses in Transplanted Patients With Donor Specific Antibodies and Chronic Rejection.移植患者中供体特异性抗体和慢性排斥反应诱导间接同种反应的激活和调节。
Transpl Int. 2024 Aug 20;37:13196. doi: 10.3389/ti.2024.13196. eCollection 2024.
10
Allogeneic HLA Humoral Immunogenicity and the Prediction of Donor-Specific HLA Antibody Development.同种异体 HLA 的体液免疫原性及供体特异性 HLA 抗体产生的预测
Antibodies (Basel). 2024 Jul 24;13(3):61. doi: 10.3390/antib13030061.